Affiliation:
1. Department of Microbiology, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492
Abstract
ABSTRACT
Drug combinations have been used to treat serious infections caused by
Pseudomonas, Burkholderia, Stenotrophomonas
, and
Acinetobacter
. In this study, the combined drug effects of gatifloxacin (GAT) and nonquinolones were determined by time-kill analysis at clinically achievable drug concentrations. Synergy (≥2 log
10
-enhanced killing at 24 h) was observed with GAT plus amikacin or a β-lactam against 50 to 75% of strains, including strains nonsusceptible to one or both drugs.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference17 articles.
1. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies
2. Synergy of ciprofloxacin and azlocillin in vitro and in a neuropenic mouse model of infection.;Chin N. X.;Eur. J. Clin. Microbiol.,1986
3. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against Gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.;Dı́ez Enciso M.;Eur. J. Clin. Microbiol. Infect. Dis.,1991
4. Antibiotic combinations: should they be tested?
5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.;Fung-Tomc J.;J. Antimicrob. Chemother.,2000
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献